Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

Aberrant epidermal growth factor (EGF) signaling is associated with tumor growth in squamous cell carcinoma of the head and neck in humans (HNSCC), and is a major focus of targeted therapy. Cetuximab, a monoclonal antibody against EGFR, has been successful at prolonging survival but has only a 10% t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ather, Ferdows, Hamidi, Habib, Fejzo, Marlena S., Letrent, Stephen, Finn, Richard S., Kabbinavar, Fairooz, Head, Christian, Wong, Steven G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2013
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3566064/
https://ncbi.nlm.nih.gov/pubmed/23405260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0056112
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak